UNSPSC 51332903: Proterguride

This classification denotes a dopamine agonist with the molecular formula C22H32N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10661OD4VE, chemically known as 1,1-diethyl-3-(6-propylergolin-8alpha-yl)urea but generally known as proterguride, which bears US NIH Compound Identifier 71999. European Medicines Agency schedules Proterguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10136MIG. The term PROTERGURIDE is an International Non-Proprietary Name.

UNSPSC 51332903 Proterguide is a Commodity code covering naloxone, drug deactivation systems, and pharmaceutical products procured by state and local health agencies, corrections departments, and cooperative purchasing organizations to support emergency response, public health, and pharmacy benefit programs. State and local governments buy under this code primarily to stock naloxone for overdose reversal in community health settings, acquire safe drug deactivation and disposal systems, and source generic pharmaceuticals and over-the-counter products through multi-state cooperative agreements. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating state and local facilities.

Recent activity shows geographic spread across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to establish direct contracting relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; this cooperative vehicle serves participating state and local government facilities across multiple states including Oregon, requiring vendors to supply through authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.